Trial ID: | L0488 |
Source ID: | NCT06381076
|
Associated Drug: |
Liposomal Curcumin
|
Title: |
High-protein Oral Supplement With Liposomal Curcumin in Adults Undergoing Hemodialysis.
|
Acronym: |
|
Status: |
RECRUITING
|
Study Results: |
NO
|
Results: |
|
Conditions: |
Chronic Kidney Disease 5D
|
Interventions: |
DRUG: Liposomal curcumin|DRUG: Food colorant
|
Outcome Measures: |
Primary: high-sensitivity C-reactive protein, baseline to end line in the concentration of high-sensitivity C-reactive protein between the control and intervention group., 12 weeks or 84 days | Secondary: Advanced glycation end products, baseline to end line in the concentration of advanced glycation end products between the control and intervention group., 12 weeks or 84 days|fatty acid byproduct - 4-hydroxynon-enal, baseline to end line in the concentration of fatty acid byproduct - 4-hydroxynon-enal between the control and intervention group., 12 weeks or 84 days|fatty acid byproduct - malondialdehyde, baseline to end line in the concentration of fatty acid byproduct - malondialdehyde between the control and intervention group., 12 weeks or 84 days|fatty acid byproduct - 8-F2 isoprostanes, baseline to end line in the concentration of fatty acid byproduct - 8-F2 isoprostanes between the control and intervention group., 12 weeks or 84 days|Klotho, baseline to end line in the concentration of klotho between the control and intervention group., 12 weeks or 84 days
|
Sponsor/Collaborators: |
Sponsor: University of Florida
|
Gender: |
ALL
|
Age: |
ADULT, OLDER_ADULT
|
Phases: |
PHASE3
|
Enrollment: |
30
|
Study Type: |
INTERVENTIONAL
|
Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
Start Date: |
2025-02-03
|
Completion Date: |
2025-12
|
Results First Posted: |
|
Last Update Posted: |
2025-02-10
|
Locations: |
University of Florida, Gainesville, Florida, 32611, United States
|
URL: |
https://clinicaltrials.gov/show/NCT06381076
|